[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368614-105":59,"doc-detail-368614-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-lentiviral-vector-targeting-a-kras-neoepitope-for-cancer-immunotherapy","A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy","","A lentiviral vector strategy was developed to target a KRAS neoepitope for cancer immunotherapy. The work uses immuno-oncotherapeutic non-integrative lentiviral vectors encoding a KRASG12D segment, either alone or with antigen carriers to enhance intracellular routing toward MHC presentation and support helper CD4+ epitopes. Treatment yielded significant immune control in colorectal and pulmonary preclinical models, linked to increased intratumoral hematopoietic cells, especially CD8+ T cells. The partial antitumor effect was robust, reproducible, and synergistic with conventional chemo- and immunotherapies.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-lentiviral-vector-targeting-a-kras-neoepitope-for-cancer-immunotherapy/368614/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-lentiviral-vector-targeting-a-kras-neoepitope-for-cancer-immunotherapy/368614.png","ImageObject",300,407,{"name":92,"@type":93},"Aditya","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-25","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What lentiviral approach was developed for KRAS neoepitope immunotherapy?","Question",{"text":112,"@type":113},"Non-integrative lentiviral vectors were engineered to encode a segment encompassing KRASG12D, either alone or combined with antigen carriers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were antigen carriers designed to improve immune presentation?",{"text":117,"@type":113},"The carriers were intended to improve intracellular antigen routing to MHC presentation machineries and/or provide universal helper CD4+ epitopes.",{"name":119,"@type":110,"acceptedAnswer":120},"What immune changes correlated with antitumor effects?",{"text":121,"@type":113},"The antitumor effects correlated with increased proportions of intratumoral hematopoietic cells, notably CD8+ T cells.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368614,1790405579,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085564549,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nA lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy  \nAnastasia Goloudina1, Fabien Le Chevalier1, Pierre Authié1, Sylvain Ciret1, Kirill Nemirov1, Ingrid Fert1, Fanny Moncoq1, Benjamin Vesin1, Amandine Noirat1, Catherine Blanc1, Yu Wei1, Pierre Charneau1,2 & Laleh Majlessi1,2􀀍  \nMutated oncogenic Kirsten rat sarcoma virus (KRAS) antigen is expressed in a large variety of cancers, including pancreatic, colorectal, and pulmonary cancers. The oncogenic KRAS mutations cause malignancies and are usually ubiquitously expressed by all cells of a tumor. The KRAS amino acid substitutions atthe positions 12 or 13 are among the most frequent mutations in human cancers. Here, we developed immuno-oncotherapeutic non-integrative lentiviral vectors encoding a segment encompassing KRASG12D, either alone, or associated with antigen carriers. These carriers can improve the intracellular antigen routing to major histocompatibility complex presentation machineries or provide universal helper CD4+ epitopes. Immunotherapy with one of these vectors resulted insignificant immune control of tumor growth in colorectal or pulmonary preclinical cancer models, in several murine genetic backgrounds. The antitumor effect was correlated with increased proportions of intra-tumoral hematopoietic cells and notably CD8+ T cells. Although this effect was partial, it was robust, reproducible and advantageously combinable with conventional chemotherapies and immunotherapies to improve antitumor protection. Therefore, this approach shows promise as an immuno-oncotherapy against KRAS-mediated malignant transformation.  \nKeywords Cancer immunotherapy, Inhibition of tumor growth, KRAS oncogenic mutations, KRASG12D, Lentiviral vectors  \nCancer is a complex and multistep disease that arises from single genetic modifications that favor cell proliferation. Each subsequent division increases the malignancy of cancer cells, making them resistant to apoptosis after DNA damage, harsh metabolic conditions and immune system attacks1. These events contribute to a rapid growth of the tumor, yet at the same time, cause accumulation of somatic mutations in the tumor cell DNA, leading to generation of cancer-specific neoantigens. The latter are absent in normal tissues but expressed by tumor cells and can be presented at their surface in the context of major histocompatibility complex (MHC) molecules2–4. Neoepitopes are well distinguished targets for cytotoxic immune T cell effectors. The vast majority of somatic mutations occurring in tumors and leading to generation of neoantigens are random and patient specific. Individual neoantigens arise relatively late during the malignant transformation and can be clonal, generating a mosaicism in terms of neoantigen repertoire presented by various cells ofa tumor, leading to tumor escape from the effector neoantigen-specific T cells. During the last decade, individual neoantigens have been used for personalized immunotherapy, and some of them reached clinical trials, for instance in pancreatic, head and neck cancers and other solid tumors (NCT05198752)5. However, the time patients can wait before receiving immunotherapy is generally limited to a few weeks. During this short post-biopsy/surgery period, neoantigens need to be identified by sequencing and data processing, and neoantigen-based personalized GMP vaccines need to be produced, all of which presents numerous challenges6,7.  \nIn contrast to personal neoantigens, a number of somatic mutations, notably in oncogenes such as KRAS (Kirsten rat sarcoma viral oncogene), PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) or ERBB2 (human epidermal growth factor receptor 2) are expressed in cancer stem cells, driving tumor initiation and maintenance. These mutations are shared by all cells of the tumor, and harbor neoantigens which can be common to patient cohorts8,9","cbCairgcPCNwpMNG","https://ap.wps.com/l/cbCairgcPCNwpMNG","pdf",3918661,17,"English","# Introduction\n## Neoantigens and personalized immunotherapy\n## Shared oncogenic mutations as common neoantigen sources\n# KRAS biology and immunotherapy rationale","[{\"question\":\"What lentiviral approach was developed for KRAS neoepitope immunotherapy?\",\"answer\":\"Non-integrative lentiviral vectors were engineered to encode a segment encompassing KRASG12D, either alone or combined with antigen carriers.\"},{\"question\":\"How were antigen carriers designed to improve immune presentation?\",\"answer\":\"The carriers were intended to improve intracellular antigen routing to MHC presentation machineries and/or provide universal helper CD4+ epitopes.\"},{\"question\":\"What immune changes correlated with antitumor effects?\",\"answer\":\"The antitumor effects correlated with increased proportions of intratumoral hematopoietic cells, notably CD8+ T cells.\"}]","A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy | PDF",1790177729,43,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b8ddac20898b2aa1ef6d304d9a7efbe7.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ee466525e7758b326b41cde079eba07e.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/089690e9b4e967cf755ae00f1313c874.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89cfe288e959ea5607467e07f8c61147.webp",980,1287]